A 6-week randomised, double-blind, parallel-group trial evaluating compatibility and safety of FIAsp and insulin aspart with an external continuous subcutaneous insulin infusion system in adult subjects with type 1 diabetes

Trial Profile

A 6-week randomised, double-blind, parallel-group trial evaluating compatibility and safety of FIAsp and insulin aspart with an external continuous subcutaneous insulin infusion system in adult subjects with type 1 diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2017

At a glance

  • Drugs Insulin aspart (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Acronyms onset 4
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 10 Jan 2017 According to a Novo Nordisk media release, the European Commission has granted marketing authorization for Fiasp for the treatment of diabetes in adults based on data from this and other three trials (231999, 226655, 232775 trials from ONSET programme).
    • 06 Jan 2017 According to a Novo Nordisk media release, Fiasp has received marketing authorization from Health Canada.
    • 04 Apr 2016 Results presented at The 98th Annual Meeting of the Endocrine Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top